Pheno.AI
Precision health from data
Tel Aviv, Israel
Operates an AI-driven data analytics platform for deep-phenotype multi-omics analysis and powers the Human Phenotype Project.
How We Help
Problem Statement
Researchers and life sciences companies lack access to large-scale, deep-phenotype multi-omics datasets needed to identify novel biomarkers, personalize treatments, and develop new drugs.
Core Technology
AI-driven data analytics platform for deep-phenotype multi-omics analysis
Key Differentiators
Provides access to a large collection of deep-phenotype multi-omics datasets; Integrates multi-omics data with imaging, continuous monitoring, and rich lifestyle data; Offers an AI-native Trusted Research Environment for secure data analysis
Clinical Focus
Precision Medicine
Company Info
- Business Model
- B2B
- Total Funding
- 6,000,000
- Website
- www.pheno.ai
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Published in Nature Medicine & Nature (2025): GluFormer validated across 19 independent cohorts (6,044 participants, 8 CGM devices, 5 countries); outperformed HbA1c in predicting diabetes and cardiovascular disease.
MedStartr Index Score
?What do you think of Pheno.AI?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.